Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes

IN BRIEF New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium–glucose cotransporter...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahady, Edward, Leahy, John L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2019
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640890/
https://www.ncbi.nlm.nih.gov/pubmed/31371851
http://dx.doi.org/10.2337/cd18-0064
Descripción
Sumario:IN BRIEF New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium–glucose cotransporter 2 inhibitors, along with considerations for their use in clinical practice.

Ejemplares similares